Author Login IJIRT Partner Network (IPN) Login

Treatment resistance in Genitourinary Cancer

  • Unique Paper ID: 172010
  • Volume: 11
  • Issue: 8
  • PageNo: 1625-1627
  • Abstract:
  • Treatment resistance in genitourinary (GU) cancers, including prostate, bladder, and kidney cancers, significantly limits the effectiveness of therapies, leading to disease progression. Resistance mechanisms include enhanced DNA repair, metabolic reprogramming, altered apoptotic pathways, immune evasion, and genetic adaptations. Chemotherapy, immunotherapy, and targeted therapies are frequently undermined by these mechanisms. Emerging strategies to overcome resistance involve combination therapies, targeting specific molecular pathways, and personalized medicine approaches. Recent advances, such as the role of circular RNAs and novel agents like belzutifan, offer promising avenues to counteract resistance and improve patient outcomes.
Download article email to a friend

Cite This Article

  • ISSN: 2349-6002
  • Volume: 11
  • Issue: 8
  • PageNo: 1625-1627

Treatment resistance in Genitourinary Cancer

Related Articles

Impact Factor
8.01 (Year 2024)
UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Archive

View More

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry